Challenges in Biomarker Discovery: Combining Expert Insights with Statistical Analysis of Complex Omics Data
- PMID: 23335946
- PMCID: PMC3548234
- DOI: 10.1517/17530059.2012.718329
Challenges in Biomarker Discovery: Combining Expert Insights with Statistical Analysis of Complex Omics Data
Abstract
INTRODUCTION: The advent of high throughput technologies capable of comprehensive analysis of genes, transcripts, proteins and other significant biological molecules has provided an unprecedented opportunity for the identification of molecular markers of disease processes. However, it has simultaneously complicated the problem of extracting meaningful molecular signatures of biological processes from these complex datasets. The process of biomarker discovery and characterization provides opportunities for more sophisticated approaches to integrating purely statistical and expert knowledge-based approaches. AREAS COVERED: In this review we will present examples of current practices for biomarker discovery from complex omic datasets and the challenges that have been encountered in deriving valid and useful signatures of disease. We will then present a high-level review of data-driven (statistical) and knowledge-based methods applied to biomarker discovery, highlighting some current efforts to combine the two distinct approaches. EXPERT OPINION: Effective, reproducible and objective tools for combining data-driven and knowledge-based approaches to identify predictive signatures of disease are key to future success in the biomarker field. We will describe our recommendations for possible approaches to this problem including metrics for the evaluation of biomarkers.
Figures
References
-
- Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95. Commentary. Provides detailed definitions and concepts of different types of biomarkers. - PubMed
-
- Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5(11):845–856. Review. A comprehensive review on different types of cancer biomarkers. - PubMed
-
- Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, Baker J, Cronin MT, Watson D, Shak S, Bohn OL, et al. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. J Clin Oncol. 2011;29 (31):4160–4167. - PMC - PubMed
-
- Konecny G, Slamon DJ. HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Williston Park) 2002;16(11):1576, 1578. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources